These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7750297)

  • 1. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.
    Muhn P; Krattenmacher R; Beier S; Elger W; Schillinger E
    Contraception; 1995 Feb; 51(2):99-110. PubMed ID: 7750297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
    Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
    Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conception and pharmacodynamic profile of drospirenone.
    Elger W; Beier S; Pollow K; Garfield R; Shi SQ; Hillisch A
    Steroids; 2003 Nov; 68(10-13):891-905. PubMed ID: 14667981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential.
    Fuhrmann U; Krattenmacher R; Slater EP; Fritzemeier KH
    Contraception; 1996 Oct; 54(4):243-51. PubMed ID: 8922878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of progestins. Focus on the novel progestin drospirenone.
    Thorneycroft IH
    J Reprod Med; 2002 Nov; 47(11 Suppl):975-80. PubMed ID: 12497671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
    Oelkers W
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):255-61. PubMed ID: 15134826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women.
    Oelkers W; Berger V; Bolik A; Bähr V; Hazard B; Beier S; Elger W; Heithecker A
    J Clin Endocrinol Metab; 1991 Oct; 73(4):837-42. PubMed ID: 1890155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers.
    Oelkers W; Helmerhorst FM; Wuttke W; Heithecker R
    Gynecol Endocrinol; 2000 Jun; 14(3):204-13. PubMed ID: 10923282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol.
    Rosenbaum P; Schmidt W; Helmerhorst FM; Wuttke W; Rossmanith W; Freundl F; Thomas K; Grillo M; Wolf A; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):16-24. PubMed ID: 10836659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of different progestogens: the special case of drospirenone.
    Sitruk-Ware R
    Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits.
    Machado RB; Pompei Lde M; Giribela AG; Giribela CG
    Womens Health (Lond); 2011 Jan; 7(1):19-30. PubMed ID: 21175386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drospirenone: a novel progestin.
    Rapkin AJ; Winer SA
    Expert Opin Pharmacother; 2007 May; 8(7):989-99. PubMed ID: 17472544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.